HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

INNOCARE (09969) rose more than 4% in the closing session, up 3.96% as of the publication, at 12.08 Hong Kong dollars, with a turnover of 44.7155 million Hong Kong dollars. On the news front, INNOCARE announced that the registration Phase 3 clinical trial of the company's newly developed BCL2 inhibitor mesutoclax (ICP-248) in combination with the BTK inhibitor ibrutinib for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has completed patient enrollment. Public information shows that mesutoclax is a novel oral highly selective BCL2 inhibitor. In addition to first-line treatment of CLL/SLL, mesutoclax is accelerating the registration clinical trial for the treatment of relapsed/refractory mantle cell lymphoma after BTK inhibitor resistance, and has been recognized by the China National Medical Products Administration (CDE) as a breakthrough therapy. In addition, clinical studies of mesutoclax for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are underway in China and globally.